These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29256535)

  • 21. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients.
    Lee MS; Kim SM; Kim SB; Lee SK; Park JS; Yang WS
    Perit Dial Int; 1999; 19(3):280-3. PubMed ID: 10433170
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure.
    Irish AB; Thompson CH
    Nephrol Dial Transplant; 1996 Nov; 11(11):2223-8. PubMed ID: 8941582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.
    Tenkanen L; Mänttäri M; Kovanen PT; Virkkunen H; Manninen V
    Arch Intern Med; 2006 Apr; 166(7):743-8. PubMed ID: 16606810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy.
    Pourshabanan P; Momeni A; Mahmoudnia L; Kheiri S
    Diabetes Metab Syndr; 2019; 13(1):132-136. PubMed ID: 30641685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
    Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study.
    Sartore G; Chilelli NC; Seraglia R; Ragazzi E; Marin R; Roverso M; Cosma C; Vaccaro O; Burlina S; Lapolla A
    Acta Diabetol; 2019 May; 56(5):505-513. PubMed ID: 30740640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gemfibrozil in the elderly. Effects on lipid metabolism].
    Brosche T; Kipfmüller G
    Fortschr Med; 1996 May; 114(13):157-60. PubMed ID: 8964557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).
    Robins SJ; Collins D; McNamara JR; Bloomfield HE
    Atherosclerosis; 2008 Feb; 196(2):849-55. PubMed ID: 17335828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
    Khan IM; Malik BR; Randhawa FA; Butt NF; Malik U; Hamid S
    J Pak Med Assoc; 2017 Dec; 67(12):1848-1852. PubMed ID: 29256528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of gemfibrozil therapy for raising high density lipoprotein levels.
    Weis S; Kudchodkar BJ; Clearfield MB; Lacko AG
    Artery; 1992; 19(6):353-66. PubMed ID: 1471924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Andrographis paniculata Extract on Triglyceride Levels of the Patients with Hypertriglyceridemia: A Randomized Controlled Trial.
    Phunikhom K; Khampitak K; Aromdee C; Arkaravichien T; Sattayasai J
    J Med Assoc Thai; 2015 Jul; 98 Suppl 6():S41-7. PubMed ID: 26434249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection.
    Ann Intern Med; 2009 Mar; 150(5):I38. PubMed ID: 19258553
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.
    Dumont M; Mauriège P; Bergeron J; Després JP; Prud'homme D
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1136-43. PubMed ID: 11477498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.